(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2011 (03.03.2011)

PCT

(10) International Publication Number
WO 2011/025947 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/519* (2006.01)
C07D 491/04 (2006.01) *A61P 35/00* (2006.01)
C07D 495/04 (2006.01)

(21) International Application Number:
PCT/US2010/046970

(22) International Filing Date:
27 August 2010 (27.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/238,108 28 August 2009 (28.08.2009) US

(71) Applicants *(for all designated States except US)*: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US). **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).

(72) Inventors; and
(71) Applicants : **ALIAGAS, Ignacio** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). **GRADL, Stefan** [DE/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). **GUNZNER, Janet** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). **MATHIEU, Simon** [CA/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). **RUDOLPH, Joachim** [DE/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). **WEN, Zhaoyang** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US). **WENGLOWSKY, Steven Mark** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(74) Agents: **HARRIS, Robert J.** et al.; Viksnins Harris & Padys PLLP, P.O. Box 111098, Saint Paul, Minnesota 55111-1098 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF



II

(57) **Abstract**: Compounds of Formula II are useful for inhibition of Raf kinases. Methods of using compounds of Formula II and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

WO 2011/025947 A1